Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 5 Recurrence 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Basal Cell 1 Keratosis, Actinic 1 Colorectal Neoplasms 1 Carcinoma, Basal Cell 1

Interventions

Oxaliplatin 270 Bevacizumab 260 Fluorouracil 249 Irinotecan 240 Leucovorin 218 Capecitabine 196 Cetuximab 161 Colonoscopy 74 Folfox protocol 70 Panitumumab 64 regorafenib 62 Drug Therapy 52 Radiotherapy 50 HMPL-013 50 Blood Specimen Collection 45 trifluridine tipiracil drug combination 43 pembrolizumab 41 Surveys and Questionnaires 35 Standard of Care 35 Nivolumab 34 Neoadjuvant Therapy 34 Surgical Procedures, Operative 33 Magnetic Resonance Spectroscopy 31 IFL protocol 27 Trifluridine 26 Interviews as Topic 26 Celecoxib 26 XELOX 25 Early Intervention, Educational 24 Specimen Handling 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Colorectal Neoplasms × 5-aminolevulinic acid hexyl ester × Clear all

NCT03272659 2019-09-18

PDD

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡